Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 234

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*

Rosenstock, J., Sankoh, S., List, J. F.·2008·Diabetes, Obesity and Metabolism

Abstract

Aim: Enhancing the physiologic actions of the endogenous incretin hormones, glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide, by inhibiting dipeptidyl peptidase‐4 (DPP‐4), the enzyme responsible for their degradation, is an emerging treatment for type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate the safety and efficacy of dose ranges of the DPP‐4 inhibitor saxagliptin (BMS‐477118) in patients with T2DM. Methods: In a 12‐week, multicentre, randomized, parallel‐group, double‐blind, placebo‐controlled trial conducted at 152 out‐patient US study centres, 338 (low‐dose cohort) and 85 (high‐dose cohort) drug‐naive patients with T2DM and inadequate glycaemic control (baseline HbA1c ≥6.8 and ≤9.7%) were randomized. Following a 2‐week washout, patients received saxagliptin 2.5, 5, 10, 20 or 40 mg once daily, or placebo, for 12 weeks (low‐dose cohort). In a second cohort, patients received saxagliptin 100 mg once daily, or placebo, for 6 weeks (high‐dose cohort). The main outcome measure was saxagliptin dose response assessed as change from baseline in HbA1c following double‐blind treatment. Results: In all treatment arms, saxagliptin significantly reduced HbA1c by 0.7–0.9% from an average baseline of 7.9% vs. placebo (0.3% reduction) in the low‐dose cohort. Placebo‐subtracted HbA1c reductions were 0.45–0.63% (low‐dose cohort). Saxagliptin had significant placebo‐subtracted reductions in fasting serum glucose (14–25 mg/dl). Postprandial glucose levels at 60 min following a standard liquid meal test were reduced by 24–41 mg/dl vs. placebo. Saxagliptin was weight neutral. Adverse events were similar across treatment groups, including placebo, with a very low incidence of confirmed hypoglycaemia in saxagliptin treatment arms. Conclusions: Saxagliptin effectively improved glycaemic control in drug‐naive patients with T2DM and was generally safe, with a tolerability profile similar to placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2008.00876.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 234

Metadata

Authors
Rosenstock, J., Sankoh, S., & List, J. F.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2008-03-18
Volume
10
Issue
5
Pages
376-386
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1971471384
Cited by
234
References
4
FWCI
25.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00876.x
The paper
Rosenstock, J., Sankoh, S., & List, J. F. (2008). Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00876.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.